The reassurance of a Recognised Investment Exchange: The Financial Conduct Authority (FCA) approved IPSX in January 2019 after a long process that included examination of IPSX’s infrastructure, trading and settlement processes, and outsourced partners. Wide appeal: The fractional ownership of ‘quasi-direct property’ through IPSX will attract the widest range of investors, e.g. retail investors will […]
Last week we were delighted to host our 16th Investor Forum at the offices of Burges Salmon in the City of London. Our audience learnt from 4 distinct companies: Severn Trent Calculus Capital Volta Finance Residential Secure Income Each company gave a 15-minute presentation that was supported by an equity research note prepared especially for the […]
Topics discussed included research, due diligence, and most importantly education. GBI Magazine stated: “Chaired by Richard Angus, Head of Business Development at Hardman & Co, the lively 2-hour session flew by with all attendees making important and occasionally surprising contributions. Nick Sharp, Head of the Co-Investment Fund at Hambro Perks described it as “a thoroughly […]
Important information This feature article has not been commissioned by AstraZeneca. It has been prepared purely for informational purposes, and is not a recommendation to readers to buy or sell AZN shares. As Hardman & Co does not trade in shares, this article is not an inducement and is, therefore, MiFID II compliant.
Our Investor Forums connect investors with companies looking for capital. It is an exclusive event for individuals seeking investment opportunities. Attendees will have the opportunity to hear from Calculus Capital, Volta Finance, Residential Secure Income and Severn Trent.
As part of the launch of the non-AIM Panel Service, last week we hosted a Round Table event bringing together professionals form across the industry to discuss the EIS market and its challenges. Hardman & Co’s Vilma Pabiliontye commented “Some of these fund managers will have been investing for many years, but have only recently […]
The average AIM stock with a market cap in excess of £600m enjoys research coverage from an average of 6.1 analysts, up 20% since the introduction of MiFID II in January 2018. Analyst resource appears to have shifted post the reforms, as coverage of FTSE 250 stocks of the same size is at 6.3 analysts, […]
Neil Martin of GBI Magazine states ‘Having reviewed the entire non-AIM Business Relief market, the firm is now creating panels of products which are tailored to the needs of an adviser’s business, and range of client profiles.
